Serum Markers of Hepatocellular Carcinoma

Overview

Journal Dig Dis Sci

Specialty Gastroenterology

Date 2010 Mar 27

PMID 20339916

Citations 83

Authors

Giulia Malaguarnera

Maria Giordano

Isabella Paladina

Massimiliano Berretta

Alessandro Cappellani

Mariano Malaguarnera

Affiliations

Soon will be listed here.

Abstract

Background: The hepatocellular carcinoma is one of the most common malignant tumors and carries a poor survival rate. The management of patients at risk for developing HCC remains intricate.

Methods: A literature search identified potential markers for hepatocellular carcinoma. These markers were analysed and justification was provided for these factors' inclusion to (or exclusion from) the markers of hepatocellular carcinoma (HCC). A search of the literature was made using cancer literature and the PubMed database for the following keywords: "markers and HCC," "Lens culinaris agglutinin reactive AFP (AFP-L3) and HCC," "Des-γ-carboxy prothrombin (DCP) and HCC," "Glypican-3 and HCC," "Chromogranin A and HCC," "Transforming growth factor β1(TGF) and HCC," "α-l-fucosidase (AFU) and HCC," "Golgi protein-73 (GP73) and HCC," "Hepatocyte growth factor (HGF) and HCC," "Nervous growth factor (NGF) and HCC."

Conclusions: Despite the large number of studies devoted to the immunohistochemistry of HCC, at the present time, the absolute positive and negative markers for HCC are still lacking, and even those characterized by very high sensitivity and specificity do not have an universal diagnostic usefulness. Given the poor response to current therapies, a better understanding of the molecular pathways active in this disease could potentially provide new targets for therapy. However, AFP shows a low sensitivity, therefore other biomarkers have been developed to make an early diagnosis and improve patients' prognosis.

Citing Articles

Nanotechnology for the Diagnosis and Treatment of Liver Cancer.

Cai Y, Wang W, Jiao Q, Hu T, Ren Y, Su X Int J Nanomedicine. 2024; 19:13805-13821.

PMID: 39735328 PMC: 11681781. DOI: 10.2147/IJN.S490661.

Three-Dimensional Structure of Novel Liver Cancer Biomarker Liver Cancer-Specific Serine Protease Inhibitor Kazal (LC-SPIK) and Its Performance in Clinical Diagnosis of Hepatocellular Carcinoma (HCC).

Lu F, Ott C, Bista P, Lu X Diagnostics (Basel). 2024; 14(7).

PMID: 38611638 PMC: 11011646. DOI: 10.3390/diagnostics14070725.

Nerve Growth Factor and the Role of Inflammation in Tumor Development.

Ferraguti G, Terracina S, Tarani L, Fanfarillo F, Allushi S, Caronti B Curr Issues Mol Biol. 2024; 46(2):965-989.

PMID: 38392180 PMC: 10888178. DOI: 10.3390/cimb46020062.

Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis.

El-Serag H, Kanwal F, Ning J, Powell H, Khaderi S, Singal A Gut. 2024; .

PMID: 38365278 PMC: 11327383. DOI: 10.1136/gutjnl-2024-332034.

Overexpression of FNDC4 constrains ovarian cancer progression by promoting cell apoptosis and inhibiting cell growth.

Li N, Li H, Zhou S, Zhang Q, Li G, Yi H J Cancer. 2023; 14(18):3416-3428.

PMID: 38021165 PMC: 10647187. DOI: 10.7150/jca.88964.

References

Malaguarnera M, Restuccia S, Di Fazio I, Zoccolo A, Trovato B, Pistone G . Serum beta2-microglobulin in chronic hepatitis C. Dig Dis Sci. 1997; 42(4):762-6. DOI: 10.1023/a:1018855928753. View

Motta M, Giugno I, Ruello P, Pistone G, Di Fazio I, Malaguarnera M . Lipoprotein (a) behaviour in patients with hepatocellular carcinoma. Minerva Med. 2001; 92(5):301-5. View

LUBIN R, Schlichtholz B, Bengoufa D, Zalcman G, Tredaniel J, Hirsch A . Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res. 1993; 53(24):5872-6. View

Ni R, Huang J, Xiao M, Li M, Meng X . Glycylproline dipeptidyl aminopeptidase isoenzyme in diagnosis of primary hepatocellular carcinoma. World J Gastroenterol. 2003; 9(4):710-3. PMC: 4611434. DOI: 10.3748/wjg.v9.i4.710. View

Preissner K, Jenne D . Vitronectin: a new molecular connection in haemostasis. Thromb Haemost. 1991; 66(2):189-94. View

Vinci E, Rampello E, Zanoli L, Oreste G, Pistone G, Malaguarnera M . Serum carnitine levels in patients with tumoral cachexia. Eur J Intern Med. 2005; 16(6):419-23. DOI: 10.1016/j.ejim.2005.02.014. View

Sassa T, Kumada T, Nakano S, Uematsu T . Clinical utility of simultaneous measurement of serum high-sensitivity des-gamma-carboxy prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoprotein in patients with small hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2000; 11(12):1387-92. DOI: 10.1097/00042737-199912000-00008. View

Yamashita F, Tanaka M, Satomura S, Tanikawa K . Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas. Gastroenterology. 1996; 111(4):996-1001. DOI: 10.1016/s0016-5085(96)70067-7. View

Malauguarnera , Di Mauro S , Laurino , Motta , Di Fazio I , Maugeri . The comorbidities of elderly oncologic patients. Arch Gerontol Geriatr. 2000; 30(3):237-244. DOI: 10.1016/s0167-4943(00)00050-9. View

10.

Rasi G, Serafino A, Bellis L, Lonardo M, Andreola F, Zonfrillo M . Nerve growth factor involvement in liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol. 2007; 13(37):4986-95. PMC: 4434623. DOI: 10.3748/wjg.v13.i37.4986. View

11.

Oka H, Saito A, Ito K, Kumada T, Satomura S, Kasugai H . Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein. J Gastroenterol Hepatol. 2002; 16(12):1378-83. DOI: 10.1046/j.1440-1746.2001.02643.x. View

12.

Bukh J, Miller R, Kew M, Purcell R . Hepatitis C virus RNA in southern African blacks with hepatocellular carcinoma. Proc Natl Acad Sci U S A. 1993; 90(5):1848-51. PMC: 45977. DOI: 10.1073/pnas.90.5.1848. View

13.

Mitsunobu M, Toyosaka A, Oriyama T, Okamoto E, Nakao N . Intrahepatic metastases in hepatocellular carcinoma: the role of the portal vein as an efferent vessel. Clin Exp Metastasis. 1996; 14(6):520-9. DOI: 10.1007/BF00115112. View

14.

Toyosaka A, Okamoto E, Mitsunobu M, Oriyama T, Nakao N, Miura K . Intrahepatic metastases in hepatocellular carcinoma: evidence for spread via the portal vein as an efferent vessel. Am J Gastroenterol. 1996; 91(8):1610-5. View

15.

Liaw Y, Tai D, Chen T, Chu C, Huang M . Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma. Liver. 1986; 6(3):133-7. DOI: 10.1111/j.1600-0676.1986.tb00279.x. View

16.

Song H, Shi W, Filmus J . OCI-5/rat glypican-3 binds to fibroblast growth factor-2 but not to insulin-like growth factor-2. J Biol Chem. 1997; 272(12):7574-7. DOI: 10.1074/jbc.272.12.7574. View

17.

Bernfield M, Gotte M, Park P, Reizes O, Fitzgerald M, Lincecum J . Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem. 2000; 68:729-77. DOI: 10.1146/annurev.biochem.68.1.729. View

18.

Tokusashi Y, Asai K, Tamakawa S, Yamamoto M, Yoshie M, Yaginuma Y . Expression of NGF in hepatocellular carcinoma cells with its receptors in non-tumor cell components. Int J Cancer. 2004; 114(1):39-45. DOI: 10.1002/ijc.20685. View

19.

Wejstal R, Norkrans G, Weiland O, Schvarcz R, Fuchs D, Wachter H . Lymphocyte subsets and beta 2-microglobulin expression in chronic hepatitis C/non-A, non-B. Effects of interferon-alpha treatment. Clin Exp Immunol. 1992; 87(3):340-5. PMC: 1554332. DOI: 10.1111/j.1365-2249.1992.tb02999.x. View

20.

Noda K, Miyoshi E, Uozumi N, Yanagidani S, Ikeda Y, Gao C . Gene expression of alpha1-6 fucosyltransferase in human hepatoma tissues: a possible implication for increased fucosylation of alpha-fetoprotein. Hepatology. 1998; 28(4):944-52. DOI: 10.1002/hep.510280408. View